ArticleNPJ vaccines2024
Continuing development of vaccines and monoclonal antibodies against Zika virus.
Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Amplification of RNA for identification of Zika and HCV in whole blood.Science advances · 2026Article
- Ten Years of Congenital Zika Syndrome: From Outbreak to a Decade of Clinical, Therapeutic, and Preventive Advances in a Tropical Disease Context.Tropical medicine and infectious disease · 2026Review
- Targeting the Zika virus envelope domains I and III as a recombinant vaccine protects mice from lethal challenge.NPJ vaccines · 2026Article
- Multivalent display of envelope protein domain III with Mi3 nanoparticles induces protective immunity against lethal Zika virus infection in mice.Virologica Sinica · 2026Article
- Synchronous Fluorescence Spectroscopy to Monitor Relevant Biochemicals over Zika-Virus-Like Particles' Production.Journal of fluorescence · 2026Article
- An updated review of Zika virus vaccine development.Clinical and experimental vaccine research · 2025Review
- Mouse strain-dependent neutralizing antibody responses to Zika virus vaccines.Journal of microbiology (Seoul, Korea) · 2025Article
- Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.The Lancet. Infectious diseases · 2025Review
- Controlled Human Infection Studies Accelerate Vaccine Development.The Journal of infectious diseases · 2025Article
- Role of non-human primate models in accelerating research and developing countermeasures against Zika virus infection.The Lancet. Microbe · 2025Review
- Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism.JCI insight · 2025Article
- A Lambda-evo (λApplied microbiology and biotechnology · 2025Article
- Article
- A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses.Frontiers in immunology · 2025Article
- Congenital Zika virus infection in laboratory animals: a comparative review highlights translational studies on the maternal-foetal interface.Memorias do Instituto Oswaldo Cruz · 2025Review
- Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques.Journal of virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.